We are live on ! Find out more
AC

Aisling Capital Portfolio holdings

AUM $45.3M
1-Year Est. Return 15.24%
This Fund
S&P 500
This Quarter Est. Return
+48.76%
1 Year Est. Return
-15.24%
3 Year Est. Return
+386.13%
5 Year Est. Return
+981.36%
10 Year Est. Return
–
AUM
$549M
AUM Growth
+$119M
Cap. Flow
-$24.5M
Cap. Flow %
-4.46%
Top 10 Hldgs %
94.5%
Holding
18
New
–
Increased
1
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$6.59M

Top Sells

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$18.3M
2
ARAV
Aravive, Inc. Common Stock
ARAV
+$8.79M
3
CEMP
Cempra, Inc.
CEMP
+$3.34M

Sector Composition

Rank Sector Weight
1 Healthcare 71.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
$176M 32.09%
4,188,920
+160,000
+4% +$6.59M
ZLTQ
2
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$89.5M 16.3%
1,609,727
– –
AIMT
3
DELISTED
Aimmune Therapeutics
AIMT
$65M 11.83%
2,990,000
– –
VRAY
4
DELISTED
ViewRay, Inc.
VRAY
$63.7M 11.59%
7,480,887
– –
ARAV
5
DELISTED
Aravive, Inc. Common Stock
ARAV
$43.2M 7.87%
337,411
-83,333
-20% -$8.79M
ESPR
6
DELISTED
Esperion Therapeutics
ESPR
$29.6M 5.38%
837,125
-800,000
-49% -$18.3M
ADMA icon
7
ADMA Biologics
ADMA
$2.03B
$17.6M 3.21%
3,608,171
– –
TTOO
8
DELISTED
T2 Biosystems, Inc
TTOO
$14.9M 2.71%
566
– –
ASXC
9
DELISTED
Asensus Surgical, Inc.
ASXC
$10.1M 1.84%
641,217
– –
PRTK
10
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$9.29M 1.69%
482,680
– –
SYRS
11
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$8.1M 1.47%
50,857
– –
CDTX
12
DELISTED
Cidara Therapeutics
CDTX
$7.96M 1.45%
51,057
– –
AGRX
13
DELISTED
Agile Therapeutics
AGRX
$5.78M 1.05%
902
– –
XENT
14
DELISTED
Intersect ENT, Inc
XENT
$3.86M 0.7%
225,000
– –
CMRX
15
DELISTED
Chimerix, Inc.
CMRX
$3.02M 0.55%
472,943
– –
PTX
16
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$777K 0.14%
210,000
– –
CEMP
17
DELISTED
Cempra, Inc.
CEMP
– –
-1,193,060
Closed -$3.34M

Similar funds

SCPM
Sagard Capital Partners Management New York $46.7M AUM 23.43% 1-Year Est. Return
ZIM
ZPR Investment Management Orange City, Florida $46.8M AUM 2.45% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return
INL
IPC/NYCG LLC New York $43.3M AUM 61.41% 1-Year Est. Return
CP
Clover Partners Dallas, Texas $43.1M AUM 4.09% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
JCM
Julex Capital Management Wellesley, Massachusetts $42.4M AUM 9.78% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return

Aisling Capital's Q1 2017 Portfolio in Review

As of Q1 2017, Aisling Capital held 18 positions worth $549M, up 28% from $430M the previous quarter. Its ten largest holdings account for 95% of the portfolio.

Aisling Capital withdrew a net $24.5M in Q1 2017, closing 1 position and reducing 2 holdings. Its most notable exit was Cempra, Inc., an estimated $3.34M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 74% a quarter earlier.

Against the trend, Aisling Capital added an estimated $6.59M to Loxo Oncology, Inc.

  • Aisling Capital added most to Loxo Oncology, Inc in Q1 2017, an estimated $6.59M increase.
  • Aisling Capital's biggest Q1 2017 reduction was Esperion Therapeutics, cutting an estimated $18.3M.
  • Aisling Capital fully exited Cempra, Inc. in Q1 2017, selling an estimated $3.34M.
  • Aisling Capital's ten largest holdings make up 95% of its $549M portfolio in Q1 2017.
  • Aisling Capital opened 0 new positions and closed 1 in Q1 2017.
  • Aisling Capital's portfolio value rose 28% quarter-over-quarter to $549M.

Based on Aisling Capital's 13F filing for Q1 2017, filed 10 May 2017.